3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
4
Genitourinary
4
Sarcoma
3
Plasma cell
3
Other hematologic neoplasm
3
Lymphoid
3
Gynecologic
3
Breast
3
Head & Neck
2
Classical hematology
2
Myeloid
1
CNS
1
Conditions
Myelodysplastic Syndromes
750
Leukemia, Myeloid, Acute
635
Leukemia
476
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
470
Precursor Cell Lymphoblastic Leukemia-Lymphoma
409
Myeloproliferative Disorders
339
Lymphoma, Non-Hodgkin
271
Leukemia, Myelomonocytic, Chronic
270
Leukemia, Lymphocytic, Chronic, B-Cell
264
Multiple Myeloma
259
Hodgkin Disease
249
Primary Myelofibrosis
230
Leukemia, Myeloid, Chronic-Phase
217
Lymphoma
203
Blast Crisis
195
Leukemia, Myeloid, Accelerated Phase
182
Lymphoma, Mantle-Cell
168
Lymphoma, Follicular
168
Burkitt Lymphoma
166
Lymphoma, Large B-Cell, Diffuse
162
Lymphoma, B-Cell, Marginal Zone
151
Congenital Abnormalities
148
Polycythemia Vera
144
Lymphoma, Large-Cell, Immunoblastic
141
Anemia, Refractory, with Excess of Blasts
131
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
128
Myelodysplastic-Myeloproliferative Diseases
126
Neoplasms, Plasma Cell
117
Thrombocythemia, Essential
114
Lymphoma, T-Cell, Cutaneous
99
Interventions
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thromboembolism
×
Myeloid
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled